New drug combination shows promise in treating advanced HER2-negative breast cancer

A study led by an Irish researcher at University College Cork found that a new drug combination shows promising results in treating advanced HER2-negative breast cancer. The combination of a histone deacetylase (HDAC) inhibitor and two types of immunotherapy led to one-in-four women having their tumors destroyed or significantly reduced. The study, led by Prof Roisin Connolly, included 24 women with HER2-negative metastatic breast cancer. The combination therapy resulted in a 25% overall response rate, with half of the participants going six months without their disease worsening. The study highlights the importance of interdisciplinary collaboration and presents a potential novel treatment approach for this patient population.

Source link

error: Content is protected !!